ORIGINAL COMMUNICATION

A 30 s test for quantitative assessment of a relative afferent pupillary defect (RAPD): the infrared pupillary asymmetry (IPA)

Nathalie Stéphanie Meneguette[1,2] · J. Emanuel Ramos de Carvalho[2,3] · Axel Petzold[2,4,5]

Abstract

Background Detection of a relative afferent pupillary defect (RAPD) by the swinging-light test can be challenging in clinical practice (dark eyes, anisocoria, dark environment). We developed a new method of RAPD quantification based on the recording of the infrared pupillary asymmetry (IPA) with a standard optical coherence tomography (OCT) device.

Methods The diagnostic value of the IPA for detection of the RAPD was determined by receiver-operating characteristic (ROC) curves and area under the curve (AUC).

Results Twenty-nine subjects were included in this study (17 controls and 12 unilateral optic neuropathies). The IPA was significantly greater in unilateral optic neuropathies (0.39) compared to controls (0.18, $p = 0.001$). The diagnostic value was good with a ROC–AUC of 0.843. Importantly, the IPA correlated significantly with the inter-eye percentage difference of the macular ganglion cell-inner plexiform layer (mGCIPL) thickness ($R = 0.53$, $p = 0.01$). Assessment of the IPA took less than 30 s.

Conclusion The present data show that the IPA is a practical and rapid test that can be applied in a clinical setting. The IPA may be a valuable functional outcome measure for clinical trials, complementing structural retinal OCT data in a biological meaningful way. The IPA should be further investigated for suitability for optic neuritis treatment trials.

Keywords Optical coherence tomography · Infrared pupillary asymmetry · IPA · Relative afferent pupillary defect · RAPD

✉ Axel Petzold
a.petzold@ucl.ac.uk

1 Department of Neurology and Ophthalmology, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil

2 Department of Neuro-ophthalmology, Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, UK

3 Department of Ophthalmology, Amsterdam UMC, AMC Amsterdam, Amsterdam, The Netherlands

4 The National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK

5 Departments of Neurology & Ophthalmology, Neuro-ophthalmology Expertise Centre, Amsterdam UMC, Amsterdam, The Netherlands

Objective

Pupillary reaction testing is a crucial step in the clinical examination of patients with optic neuropathies. The presence of a relative afferent pupillary defect (RAPD) is one of the most informative clinical signs, indicating unilateral dysfunction at the level of the afferent visual pathways [1–3]. The RAPD is not usually helpful in the situation of bilateral pathology [1]. In patients with optic neuritis, an RAPD can be detected prior to the development of inner retinal layer atrophy [2, 4–6]. Whilst clinically useful, the RAPD has not yet been included as a functional outcome measure in clinical trials and can be challenging to detect clinically in patients with dark eyes, or in the presence of anisocoria [7–9]. This is further accentuated by the need to assess the pupillary light reflex in the dark [1]. Even with an optimal setup, there remain difficulties interpreting the results, because the physiological moment-to-moment variation of the pupillomotor output results in dissimilar pupillary amplitudes and velocity profiles to the same light stimulus [8]. Finally, the test is dependent on the examiners' experience

and is subjective. Many commercially available, hand-held pupillography devices are monocular. Binocular pupillography devices are, because of their wrap around both eyes design, prone to inadvertent accommodation which can be difficult to detect to the non-experienced examiner. Both issues are severe limitations to the test and source of misinterpretation of the data.

The accurate, quantifiable assessment of the RAPD requires binocular assessment of the pupil responses in the absence of accommodation. The last decade has seen an ever-increasing use of retinal optical coherence tomography (OCT) devices not only in routine clinical practice, but also with high street opticians. Access to these devices has become relatively easy. In this study, we make use of the infrared (IR) camera of such an optical coherence tomography (OCT) device to quantify the RAPD.

Methods

This retrospective study was approved by the IRB of the Moorfields Eye Hospital, London, UK (Protocol number ROAD 17/011) in accordance with the tenets of the 1964 Declaration of Helsinki.

Study design and patient population

Retrospective data from 29 patients seen at Moorfields Eye Hospital were retrieved and assessed following consensus guidelines which had been incorporated into the trust Standard Operating Procedures (SOP) [1]. All subjects underwent a full neuro-ophthalmic examination and OCT examination on the same day and at the same site. Diagnosis of optic neuropathy was based on the clinical assessment and preceded the OCT recording.

IPA and OCT assessment

All subjects were examined with the SD-OCT (Heidelberg Engineering, Inc., Heidelberg, Germany). For assessment of the pupil response, subjects were asked to sit back from the infrared (IR) camera and look at s fixation target at 3 m distance to avoid near accommodation (Fig. 1). Room lighting was dimmed. The pupil-light response was elicited with a solar powered ophthalmoscope (Arclight®). The pupil diameters and inter-canthus distances (Fig. 2) were quantified from IR images in (1) dim light, (2) light shone into the right eye, and (3) light shone into the left eye. For each photo, the frames of the IR images were averaged for about 1 s to account for the physiological moment-to-moment variation of the pupillomotor output [8]. We also corrected for two important variables which can interfere with the reproducibility of IR pupil diameter measurements, eye-to-camera distance, and convergence.

The IPA assessment was followed by an OCT examination, as previously described [10]. No pharmacological pupil dilation was used. Data on the pRNFL were obtained using a 12° ring scan centered on the optic nerve head. Data on the macular area for the mGCIPL were acquired using a macular volume scan (20° × 20° field, 49 B-scans, vertical alignment) centred on the fovea. Automated segmentation of the pRNFL and mGCIPL was performed (Heidelberg Engineering, software version 1.10.2.0). For pRNFL thickness, the global mean of the entire pRNFL was used. For mGCIPL thickness, the average thickness of the inner four quadrants of the 1 mm, 2.22 mm, and 3.45 mm grid was calculated. Scans were excluded from the analyses if manual correction for algorithm


Fig. 1 A photograph of the setup. The subject (NSM) looks at the distant target to avoid accommodation. Note that the dark pupils are difficult to assess clinically. The IR images on the screen highlight the pupils. The assessment takes less than 30 s and can be performed even in an only moderately dimly-lit room. *IR* Infrared, *OCT* optical coherence tomography

Fig. 2 Measurements recorded for the IPA assessment. **a** Measurements from a healthy control subject with dark irides with a final IPA of 0.04. **b** Measurements from a patient with a left RAPD and dark irides with a final IPA of 0.18. An IPA of larger than 0.11 indicated an RAPD in our cohort. *IPA* Infrared pupillary asymmetry, *RAPD* relative afferent pupillary defect

segmentation failures was not possible or if the validated quality control criteria were not met (OSCAR-IB) [11].

IPA calculation

To calculate the IPA, we corrected for potential variability in distance between the eye and the camera by revising the differences between inner intercanthal distances for each measurement. A larger intercanthal distance difference indicates that the head was closer to the camera during scan acquisition. To adjust for this variation, we calculated a correction factor by dividing the baseline intercanthal distance value by the value for each measurement and each eye. The formulae presented here are for the right eye (RE). Calculations are identical for the left eye (LE):

$$\text{correction factor } R = \frac{\text{intercanthus RE}_{\text{dark}}}{\text{intercanthus RE}_{\text{light}}}. \tag{1}$$

Next, we considered the possibility of anisocoria (physiological or pathological). Therefore, we calculated the change of pupil diameter from dark (defined in formula as 'dark_r') to light (defined as 'light_r') taking the potential change of measurement distance into account. Larger values indicate a more dilated pupil. The formula applies to light shone into the RE (defined as 'light_r'). Calculations are identical for light shone into the LE:

$$\text{RE}_{\text{light}_r} = \frac{\text{light}_r \times \text{correction factor RE}}{(\text{dark}_r)}, \tag{2a}$$

$$\text{LE}_{\text{light}_r} = \frac{\text{light}_r \times \text{correction factor LE}}{\text{dark}_r}, \tag{2b}$$

$$\text{right} = \text{mean}(\text{RE}_{\text{light}_r}, \text{LE}_{\text{light}_l}). \tag{3}$$

Finally, we were able to calculate the IPA as follows:

$$\text{IPA} = \text{right} - \text{left}. \tag{4}$$

For dichotomised (RAPD yes/no) statistical analyses, we used the positive values of the IPA as: |IPA|.

To simplify the reproducibility of above approach, all formulas have been incorporated in a simple excel sheet provided as supplementary material.

Statistical analyses

Data were assessed for normality using the Shapiro–Wilk test and by graphical inspection in SAS (version 9.4). The inter-eye percentage difference (IEPD) was calculated as before [12, 13]. Because of non-Gaussian data, we used the non-parametric Kruskal–Wallis test receiver-operating characteristics (ROC) curves to calculate the area under the curve (AUC) to describe the level of diagnostic accuracy. The diagnostic value was rated as 'no or low discriminatory power' for an AUC 0.5–0.7, as 'moderate discriminatory power' for an AUC of 0.7–0.9, and as 'high discriminatory power' for an AUC > 0.9. The ROC were plotted to determine graphically optimised IPA cut-off values as the shortest distance from the top left corner to the ROC curve. The dichotomised IPA was then used to compare groups on a categorical level using the two-tailed Fisher's exact test. *p* values of < 0.05 were accepted as significant.

Results

Twenty-nine subjects were included in this retrospective study. The baseline characteristics are shown in Table 1. Seventeen were healthy controls and twelve were afflicted with a unilateral optic neuropathy secondary to multiple sclerosis, sarcoidosis, or non-arteritic anterior ischaemic

optic neuropathy. As examples for anisocoria, we had also included two patients with Holmes–Adie pupils and one with a Horner syndrome (Fig. 3). There was significant atrophy of the pRNFL in the affected eye ($p = 0.01$, Fig. 4a).

The IPA was significantly larger in subjects with an optic neuropathy (0.39) when compared to healthy control subjects (0.18, Fig. 4b, $p = 0.001$). The ROC–AUC (0.843) indicated a 'moderate discriminatory power' of the IPA to separate both groups. The optimised cut-off for the IPA was 0.11. Based on this cut-off, a significant higher proportion of patients with an optic neuropathy had a pathological IPA (58%) when compared to controls (6%, $p = 0.003$). There was a linear relationship between the IPA and the mGCIPL-IEPD ($R = 0.53$, Fig. 4c, $p = 0.0$). For the pRNFL-IEPD, there was no such relationship ($R = 0.16$, $p = 0.52$).

Table 1 Patient characteristics. The median (IQR) and mean (SD) are shown. The pRNFL and macular GCIPL are given for the better and worse (atrophy) eye

Characteristics	Control	Optic neuropathy	p value
Age (years)	34 (28–48)	44 (42–57)	0.046
Gender (F:M)	10:7	7:5	
IPA	0.06 ± 0.05	0.17 ± 0.11	0.0019
pRNFL (worse eye) [μm]	99 ± 18	71 ± 20	0.011
pRNFL (better eye) [μm]	97 ± 17	92 ± 12	NS
IEPD-pRNFL	7.36 ± 11.02	12.85 ± 11.02	0.037
GCIPL (worse eye) [mm³]	0.40 ± 0.08	0.29 ± 0.08	0.018
GCIPL (better eye) [mm³]	0.41 ± 0.09	0.40 ± 0.05	NS
IEPD-GCIPL	8.2 ± 12	13 ± 12	NS

NS Not significant, *GCIPL* ganglion cell-inner plexiform layer, *IEPD* inter-eye percentage difference, *IPA* infrared pupillary asymmetry, *pRNFL* peripapillary retinal nerve fibre layer

Discussion

This retrospective study suggests that the IPA provides a rapid and quantifiable metric for the RAPD in cases with unilateral pathology. There are two novel observations. First, there is a physiological IPA. Second, the IPA correlates with the macular GCIPL. Therefore, the IPA is biological meaningful. Finally, the IPA can be reliably assessed and documented in clinically challenging situations. The calculation of the IPA is straightforward, and we provide an excel worksheet practical equation for the readers to test and validate the IPA in their clinical practices.

Consistent with the previous work, the intercanthal distances were taken as reference point so as to overcome the variability induced by differences in positional acquisition of the scans. The previous studies have shown a correlation between the presence of an RAPD and pRNFL and mGCIPL [4], the latter deemed more sensitive as opposed to the pRNFL [2]. A positive RAPD, as assessed by an experience clinician, is expected to become subjectively visible only once at least 25% of the pRNFL has been atrophied [5]. In our study, we used a highly sensitive measure, the IEPD [12, 13]. The finding of a significant linear relationship between the mGCIPL-IEPD and IPA is important, because the IPA could be a valuable functional outcome measure to complement structural OCT data in clinical trials and research. This will require independent confirmation as there will be a likely need for validation of the inter-laboratory IPA cut-off points with differences in device settings, lighting conditions, and distance to IR camera. Finally, the IPA allows the diagnosis of anisocoria, such as from a Horner Syndrome [10] or a Holmes–Adie pupil which is clinically relevant.

The novel, but logical findings from this study are first a "physiologically RAPD". Second, the strong correlation between the IPA and the inter-eye difference of the GCIPL thicknesses is biologically meaningful. The eye with a higher macular GCIPL density elicits, compared to the contralateral

Fig. 3 Pupillary reactions demonstrated by photos of the IR camera of the Spectralis SD-OCT device. **a** The IPA for the right RAPD is 0.20. **b** A left Horner Syndrome with greater anisocoria in the dark (IPA = 0.01). **c** A left Holmes–Adie pupil with greater anisocoria in light (IPA = 0.05). An IPA greater than 0.11 indicated an RAPD in our cohort. *IPA* infrared pupillary asymmetry, *IR* infrared, *RAPD* relative afferent pupillary defect, *SD-OCT* spectral-domain optical coherence tomography

Fig. 4 a The pRNFL of the better (red bar) and worse (blue bar) eyes are shown for controls and patients. There was a statistically significant amount of atrophy in the affected (blue bar) eye ($p=0.01$). *pRNFL* Peripapillary retinal nerve fibre layer. **b** The IPA was significantly higher in patients with an optic neuropathy when compared to control subjects ($p=0.001$). *IPA* Infrared pupillary asymmetry. **c** There is a linear relationship ($R=0.53$, $p=0.01$) between the IPA and the IEPD for the ganglion cell-inner plexiform layer density (GCIPL-IEPD). *GCIPL* Ganglion cell-inner plexiform layer, *IEPD* inter-eye percentage difference, *IPA* infrared pupillary asymmetry

eye, a stronger light response which will result in a relative stronger pupil constriction. A physiological RAPD has not been described previously, but can be implied indirectly from results based on the use of neutral density filters for the calibration of a commercial pupillography device [14]. In their method paper, the authors showed that an RAPD could be induces by placing 0.0, 0.3, 0.6, and 0.9 log units neutral density filters in front of one healthy eye. Neutral density filters have also been used to accentuate the RAPD [14]. In clinical practice, however, assessment of the RAPD by placing a dark object in front of an already dark eye does make assessment of the pupil response even more difficult. For this reason, we have not used this approach in our routine clinical practice, other than for bedside teaching purposes in a subject with light blue irises. Future prospective studies aiming to validate the IPA for a multi-center setting will need to consider the calibration of the method with neutral density filters in subjects to travel around sides and be re-assessed

across the variable setups. This clearly was beyond the scope of this retrospective study.

One important conclusion from the observation of a physiological RAPD is that there will be a need to determine and validate a normal range for the IPA in a multi-center setting. This is a crucial paradigm shift from the classical clinical teaching which was based on a subjective yes/no answer to whether or not a RAPD was present in the diagnostic work up of a patient with a suspected optic neuropathy. The new question is when does the IPA become pathological. This will require the validation of the here proposed cut-off of 0.11 for the IPA in a multi-center setting. Similar to lessons learned from the other clinical tests, we anticipate that, during this validation process, a list of other relevant variables will emerge which we have not yet identified. Factors which likely will require to be investigated prospectively relate to opacities in the visual pathway, visual field defects of variable size and location and outer retinal layer pathology

not reflected in pRNFL and mGCIPL atrophy. The IPA is unlikely to be valid in cases of bilateral optic nerve pathology, just as the RAPD can be absent in these cases [1].

Our findings are also consistent with another new approach for detection of the RAPD, ultrasound, which has been published, whilst our paper was under review [15]. The study by Schmidt et al. was of comparable patient numbers and took only 5 min per patient. The authors found a reduced constriction amplitude of the pupil in the affected eye and calculated a constriction ratio. They concluded that a cut-off of this constriction ratio of > 1.3 was useful in discriminating eyes with an RAPD from healthy controls. The constriction ratio correlated with visual acuities, but OCT data have not been available.

In conclusion, the IPA is a practical, easily applied, and quick test for quantitative assessment of the RAPD in patients with a suspected optic neuropathy, even in clinically challenging situations. The novel observation of a physiological RAPD and the biological meaningful correlation of the IPA with macular GCIPL structure could introduce a paradigm shift from the RAPD as a subjective bedside expert opinion to become a valuable quantitative measure worthwhile to undergo multi-center validation as a promising secondary outcome marker for clinical trials.

Compliance with ethical standards

Conflicts of interest Axel Petzod is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. He is member of the steering committee for the OCTiMS study (Novartis) and performed OCT QC for the PASSOS study (Novartis) and received consulting fees. J. Emanuel Ramos de Carvalho and Nathalie Stéphanie Meneguette declare that they have no conflict of interest.

References

1. Petzold A, Wattjes MP, Costello F et al (2014) The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol 10(8):447–458

2. Besada E, Frauens BJ, Makhlouf R et al (2018) More sensitive correlation of afferent pupillary defect with ganglion cell complex. J Optom 11(2):75–85

3. Blazek P, Davis SL, Greenberg BM et al (2012) Objective characterization of the relative afferent pupillary defect in MS. J Neurol Sci 323(1–2):193–200

4. Chilińska A, Ejma M, Turno-Kręcicka A et al (2016) Analysis of retinal nerve fibre layer, visual evoked potentials and relative afferent pupillary defect in multiple sclerosis patients. Clin Neurophysiol 127(1):821–826

5. Nakanishi Y, Nakamura M, Tatsumi Y et al (2006) Quantification of retinal nerve fiber layer thickness reduction associated with a relative afferent pupillary defect. Graefes Arch Clin Exp Ophthalmol 244(11):1480–1484

6. Takizawa G, Miki A, Maeda F et al (2015) Association between a relative afferent pupillary defect using pupillography and inner retinal atrophy in optic nerve disease. Clin Ophthalmol 9:1895–1903

7. Kardon RH, Hong S, Kawasaki A (2013) Entrance pupil size predicts retinal illumination in darkly pigmented eyes, but not lightly pigmented eyes. Invest Ophthalmol Vis Sci 54(8):5559–5567

8. Kawasaki A, Moore P, Kardon RH (1995) Variability of the relative afferent pupillary defect. Am J Ophthalmol 120(5):622–633

9. Sharma S, Baskaran M, Dhara R et al (2016) Factors influencing the pupillary light reflex in healthy individuals. Graefes Arch Clin Exp Ophthalmol 254(7):1353–1359

10. Pellegrini F, Capello G, Napoleone R (2018) Dilation lag in Horner syndrome can be measured with a diagnostic imaging system. Neurology 90(13):618

11. Tewarie P, Balk L, Costello F et al (2012) The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One 7(4):e34823

12. Coric D, Balk LJ, Uitdehaag BMJ et al (2017) Diagnostic accuracy of optical coherence tomography inter-eye percentage difference (IEPD) for optic neuritis in multiple sclerosis. Eur J Neurol 24(12):1479–1484

13. Nolan RC, Galetta SL, Frohman TC, Frohman EM, Calabresi PA, Castrillo-Viguera C et al (2018) Optimal intereye difference thresholds in retinal nerve fiber layer thickness for predicting a unilateral optic nerve lesion in multiple sclerosis. J Neuroophthalmol 38:451–458

14. Shwe-Tin A, Smith GT, Checketts D et al (2012) Evaluation and calibration of a binocular infrared pupillometer for measuring relative afferent pupillary defect. J Neuroophthalmol 32(2):111–115

15. Schmidt FA, Connolly F, Maas MB et al (2018) Objective assessment of a relative afferent pupillary defect by B-mode ultrasound. PLoS One 13(8):e0202774